The second drug, FT-7051, is an oral, potent, and selective inhibitor of p300/CBP with activity in preclinical models of prostate cancer, including models which are resistant to the currently used AR inhibitors such as enzalutamide. The gene discussed is AR; the disease is prostate cancer.